Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MNV 201

Next Previous
Drug Profile

MNV 201

Alternative Names: Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria - Minovia Therapeutics; CD34+ cells enriched with allogeneic placenta derived mitochondria - Minovia Therapeutics; MNV BM PLC; MNV-201; MNV-PLC

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Minovia Therapeutics
  • Class Antineoplastics; Haematopoietic stem cells therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II VLCAD deficiency
  • Phase I Myelodysplastic syndromes

Most Recent Events

  • 20 Nov 2025 Adverse events and pharmacodynamics data from a phase Ib trial in Myelodysplastic syndromes released by Minovia Therapeutics
  • 15 Oct 2025 MNV 201 receives Orphan Drug status for Myelodysplastic syndromes in USA
  • 18 Sep 2025 Phase-II clinical trials in VLCAD deficiency (In children) (IV) before September 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top